Evidence map›Paper›PMID 41278312›Full record

ArticleKidney international reports2025

Efficacy of Rituximab as Adjunctive Therapy to Immunosuppressive Agents in Adult Primary Focal Segmental Glomerulosclerosis.

Osama Nady Mohamed, Marwa Ibrahim Mohamed, Shereen Mohammed Mohammed Elsaghir, Shimaa Abdelrazek, Aml Azzam, Tarek Mahmoud Senosy Mohamed, Hassan M H Mohammed, Rasha Yousef, Ayman Ahmed Abd Rabou, Reem Y Abdelazeem Elgarhy and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Osama Nady MohamedDepartment of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Marwa Ibrahim MohamedDepartment of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Shereen Mohammed Mohammed ElsaghirDepartment of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Shimaa AbdelrazekDepartment of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Aml AzzamDepartment of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Tarek Mahmoud Senosy MohamedDepartment of Cardiology, Faculty of Medicine, Minia University, Minia, Egypt.
Hassan M H MohammedDepartment of Cardiology, Faculty of Medicine, Minia University, Minia, Egypt.
Rasha YousefDepartment of Clinical Pathology, Faculty of Medicine, Minia University, Minia, Egypt.
Ayman Ahmed Abd RabouDepartment of Clinical Pathology, Faculty of Medicine, Minia University, Minia, Egypt.
Reem Y Abdelazeem ElgarhyDepartment of Clinical Pathology, Faculty of Medicine, Minia University, Minia, Egypt.
Alaa Khalifa Mohamed MahdyDepartment of Clinical Pathology, Faculty of Medicine, Minia University, Minia, Egypt.
Mohamed Ahmed AbdelsamieDepartment of Radiology, Faculty of Medicine, Minia University, Minia, Egypt.
Manar M SayedDepartment of Radiology, Faculty of Medicine, Minia University, Minia, Egypt.
Eman FathiDepartment of Public and Preventive Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Nermeen Dahi Mohammed ToniDepartment of Public and Preventive Medicine, Faculty of Medicine, Minia University, Minia, Egypt.
Rabeh Khairy SalehDepartment of Pathology, Faculty of Medicine, Minia University, Minia, Egypt.
Basma FathyDepartment of Internal Medicine, Faculty of Medicine, Minia University, Minia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Primary focal segmental glomerulosclerosis (FSGS) is a rare, likely immune-related disease. Rituximab (RTX) may help manage it, but existing adult data are limited and mainly based on case reports or case series. We aimed to evaluate RTX treatment outcomes in a large, multicenter adult cohort. Methods: This was a retrospective study of 160 patients with primary FSGS treated with RTX as adjunctive therapy to standard immunosuppressive agents between March 2015 and June 2023, that evaluated treatment responses at 3, 6, and 12 months, followed by an extended 24-month follow-up to assess long-term outcomes. Treatment outcomes included complete response (CR), partial response (PR), or no response. Treatment-related adverse effects and relapse-free survival (RFS) were evaluated at each visit. Patients undergoing RTX retreatment and those monitored for an extended 24-month period were analyzed independently. Results: Response rates at 3, 6, and 12 months were 57%, 71%, and 74%, respectively. Twelve-month RTX response was positively associated with lower baseline 24-hour proteinuria (odds ratio [OR] = 0.49, Conclusion: RTX shows promise in treating primary FSGS, particularly in steroid-dependent patients, those with less severe nephrotic syndrome, and previous responders. RTX offers durable responses for most patients, but long-term management remains challenging in those who relapse and need retreatment.

Indexed as

calcineurin inhibitorsfocal segmental glomerulosclerosisrituximabsteroid dependencysteroid resistance

Identifiers

PMID41278312
PMCPMC12640038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.